Wouter T Zandee

Suggest Changes
Learn More
Background Assessment of clinical benefit of systemic treatments of rare diseases including gastroenteropancreatic neuroendocrine tumours (GEP-NET) is challenging. Recently several tools have been(More)
  • 1